BRCA1 and ovarian carcinoma: Conversely, in women, with BRCA1/2 gene mutations, the risk for ovarian cancer is strongly reduced by OC use [33] via exerting an advantageous estrogen-like effect by the indirect activation of the AF2 domain [17].